Humoral and Cellular Immunogenicity and Safety of 3-Dose Inactivated COVID-19 Vaccine in Young Children Less Than 5 Years With Kidney Diseases

• DOI: 10.1016/j.ekir.2023.08.012
• Publication Date: 2023-08-19T21:24:20Z
• Authors: Eugene Yu-Hin Chan; Daniel Leung; Samuel M.S. Cheng; Jaime S. Rosa Duque; Xiaofeng Mu; Fanny Tsz-Wai Ho; Pak-Chiu Tong; Wai-Ming Lai; Matthew H.L. Lee; Stella Chim; Issan Y.S. Tam; Leo C.H. Tsang; Kelvin K.H. Kwan; Yuet Chung; Howard H.W. Wong; Amos M.T. Lee; Wing Yan Li; Summer T.K. Sze; Jennifer H.Y. Lam; Derek H.L. Lee; Sau Man Chan; Wenwei Tu; Malik Peiris; Alison Lap-Tak Ma; Yu Lung Lau
• Keywords: Immunosuppression; Tolerability; Antibody response

There is no available data pertaining to humoral and cellular response against COVID-19 among young children with kidney diseases following inactivated vaccine.1Han B. Song Y. Li C. Yang W. Ma Q. Jiang Z. M. Lian X. Jiao Wang L. et al.Safety, tolerability, immunogenicity of an SARS-CoV-2 vaccine (CoronaVac) in healthy adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.Lancet Infect Dis. 2021; 21: 1645-1653https://doi.org/10.1016/S1473-3099(21)00319-4Abstract Full Text PDF PubMed Scopus (195) Google Scholar We therefore evaluated the safety 3-dose CoronaVac at accelerated schedule (0.5ml; day 0, 14, 28) prospective study Hong Kong (COVAC; NCT04800133) (Supplementary Methods).2Ma A.L.-T. Leung D. Chan E.Y.-H. Chim S. Cheng Ho F.T.-W. Lai W.-M. Tong P.-C. Lee M.H.-L. Wong W.H.-S. al.Antibody responses 2 doses mRNA pediatric patients diseases.Kidney International. 2022; 101: 1069-1072Abstract (6) Sixty-four were enrolled five (median age 3.3 years, IQR 3.1-3.6; 3 females; Chinese) analyzed (glomerular disease on immunosuppression, n=2; aCKD, failure, n=1). (Table S1) tracked antibody our wild-type (WT) SARS-CoV-2, including S-RBD IgG for binding surrogate virus neutralization test (sVNT) longitudinally from pre-vaccine baseline post-dose (Fig. 1A 1B).3Rosa Duque J.S. S.M.S. Cohen C.A. Mu Hachim A. Zhang S.M. Chaothai al.Immunogenicity reactogenicity vaccines BNT162b2 adolescents.Nat Commun. 13: 3700https://doi.org/10.1038/s41467-022-31485-zCrossref (18) After doses, all seropositive had high geometric mean sVNT% level 94.0%, increases titers successive doses. also studied IFN-γ+ antiviral CD4+ helper CD8+ cytotoxic T-cell S, N M proteins 2). detected significant increase SNM-specific 5 2B). Other such as IL-2 showed increasing trend S1A-D). Importantly, demonstrated S-specific or responses. When compared WT response, we found significantly lower Omicron BA.1 (post-dose 3, 94.0% vs 17.9%, P=0.0012) S2A), indicating partial escape. Nonetheless, similar between S2B-D).4Leung Rosa Tam I.Y.S. after third dose adolescents.Front Immunol. 2023; 141106837https://doi.org/10.3389/fimmu.2023.1106837Crossref (0) In addition, noticed comparable these subjects aged 3-5 who recruited another subgroup same S3A-B). that was safe tolerable patients, breakthrough infections reported median 118 days (IQR 111-132 days) (Supplemental text 1 Fig. S4). conclusion, accelerated, vaccination safe, elicited satisfactory diseases. appeared preserved BA.1, which prevent severe COVID-19. The authors declare conflicts interest. Y.L. Lau conceptualized study. Lau, Peiris, Tu, Leung, Duque, designed led acquisition funding. Peiris supervised project. Chan, Mu, Cheng, Tam, J.H.Y. Lam administrative procedures. A.L.T. Ma, E.Y.H. Chim, F.T.W. Ho, P.C. Tong, W.M. Lai, M.H.L. provided study-related assessments follow-up. S.T.K. Sze, Lam, collected data. L.C.H. Tsang, K.K.H. Kwan, developed performed sVNT. Chung, H.H.W. Wong, A.M.T. Lee, W.Y. Li, Tu T cell assays. D.H.L. curated, analyzed, visualized validated drafted manuscript by input Cheng. All reviewed approved final manuscript. thank staff Community Vaccination Centers Ap Lei Chau Sports Centre, Gleneagles Hospital Kong, Sun Yat-Sen Memorial Park University Health System. investigators are grateful research team members laboratory Department Pediatrics Adolescent Medicine their support. most thankful participants, well clinicians have care testing patients. FUNDING This supported grants COVID19F02, COVID19F10, COVID19F12 SAR Government, not involved design, performance, interpretation, publication this DATA SHARING requests share pseudonymized underlying conclusions paper researchers will be facilitated authors, subject ethics approval. Enquiries should addressed [email protected]. Download .pdf (2.33 MB) Help pdf files